Open Access

YRDC is upregulated in non‑small cell lung cancer and promotes cell proliferation by decreasing cell apoptosis

  • Authors:
    • Haibo Shen
    • Enkuo Zheng
    • Zhenhua Yang
    • Minglei Yang
    • Xiang Xu
    • Yinjie Zhou
    • Junjun Ni
    • Rui Li
    • Guofang Zhao
  • View Affiliations

  • Published online on: April 21, 2020     https://doi.org/10.3892/ol.2020.11560
  • Pages: 43-52
  • Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer‑associated mortality worldwide. yrdC N6‑threonylcarbamoltransferase domain containing protein (YRDC) has been demonstrated to be involved in the formation of threonylcarbamoyladenosine in transfer ribonucleic acid. However, the molecular mechanisms underlying NSCLC progression remain largely unclear. The present study revealed that YRDC was upregulated in NSCLC samples compared with adjacent non‑cancerous tissues by analyzing datasets obtained from the Gene Expression Omnibus and The Cancer Genome Atlas. Higher expression of YRDC was associated with overall survival time and disease‑free survival time in patients with NSCLC, particularly in lung adenocarcinoma. Furthermore, knockdown of YRDC in NSCLS cell lines significantly suppressed cell growth and cell colony formation in vitro. Additionally, the results demonstrated that silencing of YRDC induced apoptosis of A549 cells. Then, the protein‑protein interaction networks associated with yrdC N6‑threonylcarbamoltransferase domain containing protein (YRDC) in NSCLC were subsequently constructed to investigate the potential molecular mechanism underlying the role of YRDC in NSCLC. The results revealed that YRDC was involved in the regulation of spliceosomes, ribosomes, the p53 signaling pathway, proteasomes, the cell cycle and DNA replication. The present study demonstrated that YRDC may serve as a novel biomarker for the prognosis prediction and treatment of NSCLC.

Related Articles

Journal Cover

July 2020
Volume 20 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Shen, H., Zheng, E., Yang, Z., Yang, M., Xu, X., Zhou, Y. ... Zhao, G. (2020). YRDC is upregulated in non‑small cell lung cancer and promotes cell proliferation by decreasing cell apoptosis. Oncology Letters, 20, 43-52. https://doi.org/10.3892/ol.2020.11560
MLA
Shen, H., Zheng, E., Yang, Z., Yang, M., Xu, X., Zhou, Y., Ni, J., Li, R., Zhao, G."YRDC is upregulated in non‑small cell lung cancer and promotes cell proliferation by decreasing cell apoptosis". Oncology Letters 20.1 (2020): 43-52.
Chicago
Shen, H., Zheng, E., Yang, Z., Yang, M., Xu, X., Zhou, Y., Ni, J., Li, R., Zhao, G."YRDC is upregulated in non‑small cell lung cancer and promotes cell proliferation by decreasing cell apoptosis". Oncology Letters 20, no. 1 (2020): 43-52. https://doi.org/10.3892/ol.2020.11560